Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
2005 1
2007 3
2008 1
2009 7
2010 4
2011 6
2012 1
2013 1
2014 7
2015 5
2016 5
2017 5
2018 6
2019 7
2020 7
2021 3
2022 6
2023 4
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. Beelen DW, et al. Among authors: grigoleit gu. Lancet Haematol. 2020 Jan;7(1):e28-e39. doi: 10.1016/S2352-3026(19)30157-7. Epub 2019 Oct 9. Lancet Haematol. 2020. PMID: 31606445 Clinical Trial.
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Beelen DW, Stelljes M, Reményi P, Wagner-Drouet EM, Dreger P, Bethge W, Ciceri F, Stölzel F, Junghanß C, Labussiere-Wallet H, Schaefer-Eckart K, Grigoleit GU, Scheid C, Patriarca F, Rambaldi A, Niederwieser D, Hilgendorf I, Russo D, Socié G, Holler E, Glass B, Casper J, Wulf G, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, La Rocca U, Finke J, Benedetti F, Pichlmeier U, Klein A, Baumgart J, Markiewicz M. Beelen DW, et al. Among authors: grigoleit gu. Am J Hematol. 2022 Aug;97(8):1023-1034. doi: 10.1002/ajh.26620. Epub 2022 Jun 8. Am J Hematol. 2022. PMID: 35617104 Free article. Clinical Trial.
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.
Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf T, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Ruhnke L, et al. Among authors: grigoleit gu. Blood Adv. 2025 Mar 25;9(6):1392-1404. doi: 10.1182/bloodadvances.2024013304. Blood Adv. 2025. PMID: 39504561 Free PMC article.
CMV-specific T cell therapy.
Einsele H, Kapp M, Grigoleit GU. Einsele H, et al. Among authors: grigoleit gu. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):71-5. doi: 10.1016/j.bcmd.2007.07.002. Epub 2007 Sep 11. Blood Cells Mol Dis. 2008. PMID: 17851094 Review.
T-cell therapy for cytomegalovirus infection.
Mui TS, Kapp M, Einsele H, Grigoleit GU. Mui TS, et al. Among authors: grigoleit gu. Curr Opin Organ Transplant. 2010 Dec;15(6):744-50. doi: 10.1097/MOT.0b013e32834016b9. Curr Opin Organ Transplant. 2010. PMID: 20930639 Review.
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.
Dührsen U, Bockisch A, Hertenstein B, Karsten IE, Kroschinsky F, Heuser M, Hochhaus A, Höffkes HG, Behringer D, Prange-Krex G, Tometten M, Grieshammer M, Grigoleit GU, Schmalz O, Jordan K, Bernhard H, Gaska T, Giagounidis A, Schroers R, Martens UM, Held G, Klapper W, Jöckel KH, Nonnemacher M, Hüttmann A; PETAL Trial Investigators. Dührsen U, et al. Among authors: grigoleit gu. Blood Neoplasia. 2024 May 21;1(3):100018. doi: 10.1016/j.bneo.2024.100018. eCollection 2024 Sep. Blood Neoplasia. 2024. PMID: 40453056 Free PMC article. Clinical Trial.
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors.
Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, Medina T, Ziemer M, Whitman E, Finckenstein FG, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik AA. Kluger H, et al. Among authors: grigoleit gu. Cancer Commun (Lond). 2025 Jul 22. doi: 10.1002/cac2.70050. Online ahead of print. Cancer Commun (Lond). 2025. PMID: 40693376 No abstract available.
74 results